US EditionTeva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Summary by Inside Ottawa Valley
3 Articles
3 Articles
All
Left
2
Center
Right
Guelph Mercury+2 Reposted by 2 other sources
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278Partnership leverages strategic relationships to enable research and…
·Guelph, Canada
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left2Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
